TRANEXAMIC ACID MATTERs

iPhoneIcon_Big (2)After the military showed benefit of tranexamic acid (TXA) in trauma, it was successfully tested in the large CRASH-2 trial, showing great benefit in civilians as well. Moving back to war zone trauma, MATTERs – Military Application of Tranexamic acid in Trauma Emergency Resuscitation Study – brings additional evidence that TXA is good for your trauma patient – and that the greatest benefit is in the most injured patients receiving massive transfusions.

MATTERs
This was a retrospective study, looking at military trauma patients from 2009-2010 requiring transfusion. In this time frame TXA was at first optional, and after 2010 implemented for patients receiving blood products or with sign of fibrinolysis on ROTEM. Later, of course, TXA has since been instituted for all major trauma suspected of bleeding as per CRASH-2.

The CRASH-2 protocol is TXA 1g as soon as possible (and within 3 hours of the injury). Then, another 1g as an infusion over the next 8 hours. We wrote about CRASH-2 a few years back here (Swedish text). This military trial used TXA 1g bolus, only repeated if the clinician felt it necessary. No-one really knows the optimal dose to use or at what infusion rates, but the CRASH-2 protocol has shown its worth, so I guess we’re sticking with it for now.

896 patients admitted with combat injury requiring transfusion. 293 received TXA and 603 didn’t. Looking at the MATTERs data, these are serious trauma patients! ISS around 25, and over 300 patients got massive transfusions, receiving an average of over 20 PRBCs.

Other usual suspects
Looking at the data, more of the patients receiving TXA also recieved cryoprecipitate. This makes sense, as TXA was on indication, these patients would also often receive other coagulo-enhancing drugs. It also fits with the TXA given to more of the massive transfusion patients and the TXA group looking slightly sicker. As TXA became more popular with time, there might be other advances in trauma care helping the patients in the TXA group. Still, the major difference between the two groups seems to be TXA.

Results
When considering all patients in this study, the TXA group had a 17% mortality vs 23% for the no-TXA group. That’s already impressive. Graphs below.

TXA overall and massive transf mort

Left graph showing cumulative survival for TXA vs no TXA for all patients – but look at just the ones needing massive transfusions (right graph), and you’ll find the TXA group has kept roughly the same mortality: 14%, while the no TXA mortality has increased to 28%! The relatively small cohort probably makes the statistical illusion of the hardest injured TXA patients having a better survival than the overall TXA survival. At best, it should be the same.

Any downsides? We’ve all been surprised TXA has shown so few thromboembolic complications. In this study, more patients got pulmonary embolisms and DVTs. Around 2-3% risk of PE or DVT in the TXA group vs 0% in the no TXA group.

Conclusion
This trial is adding to the evidence of TXA benefit, and also showing TXA might have the highest benefit in the most severely bleeding patients.

Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study, Arch Surg, 2012 (Full Text).

This entry was posted in Emergency Medicine, Trauma. Bookmark the permalink.

4 Responses to TRANEXAMIC ACID MATTERs

  1. nfkb says:

    Thank you for this post !

    In our trauma center we are strong believers in the TXA utilization.
    But beeing a tertiary make sometims difficult to administer ASAP the TXA. Prehospital care administration is really important since some patients are moved from a primary care facilty to the tertiary care with > 2-4 hours delay.

    (every time i push TXA i think DVT, a patient who bleeds is always at risk of DVT to my eyes. Especially in obstetrics, cancer and trauma patients. i.e. a month a go reintervention for hematoma after ENT cancer surgery, 3 day later tachycardia, echocardiographic nailed the diag with a McConnel Sign -> PE 🙁 )

  2. Paul Jones says:

    Great post, thank you for sharing. Love how repeated trials are continuing to show great benefit for the use of TXA. It is such a simple intervention which appears to make such a significant difference in mortality. I certainly have raised it in the resus bay multiple times with staff EM/Critical care providers or trauma surgeons, sad that the response has been so mixed thus far when the evidence as I read it is so compelling for benefit. Love the blog. Keep up the great work.

  3. Pingback: Journal Club March | WikEM Blog

  4. Pingback: The LITFL Review 123 - LITFL

Leave a Reply

Your email address will not be published. Required fields are marked *